Johnson & Johnson wins FDA De Novo clearance for OTTAVA robotic surgery system in US

• FDA granted De Novo market authorization for Johnson & Johnson’s OTTAVA robotic surgical system in the U.S.
• Cleared for multiple upper-abdominal general surgery procedures, including bariatric surgery, gallbladder removal, appendectomy.
• Company plans a limited U.S. commercial launch with select customers while pursuing additional indications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via Business Wire (Ref. ID: 202607220700BIZWIRE_USPR_____20260717_BW254564) on July 22, 2026, and is solely responsible for the information contained therein.